Circulating microRNAs in pancreatic juice as candidate biomarkers of pancreatic cancer

Journal of Cancer

Volumn 5, Issue 8, 2014, Pages 696-705

  Wang, Jin ^a   Raimondo, Massimo ^b,c   Guha, Sushovan ^c   Chen, Jinyun ^a   Diao, Lixia ^a   Dong, Xiaoqun ^d   Wallace, Michael B ^b,c   Killary, Ann M ^a,e   Frazier, Marsha L ^a,e   Woodward, Timothy A ^b,c   Wang, Jing ^a   Sen, Subrata ^a,e  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF RHODE ISLAND   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

Biomarker; Circulating; miRNA; Pancreatic cancer; Pancreatic juice

Indexed keywords

CA 19-9 ANTIGEN; MICRORNA; MICRORNA 1427; MICRORNA 205; MICRORNA 210; MICRORNA 492; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CHRONIC PANCREATITIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS JUICE; PANCREAS SECRETION; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION;

EID: 84912111257     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.10094     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010, 60(5):277-300.
2. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 1995, 221(6):721-731.
3. Ohuchida K, Mizumoto K, Fujita H, et al. Sonic hedgehog is an early developmental marker of intraductal papillary mucinous neoplasms: clinical implications of mRNA levels in pancreatic juice. J Pathol. 2006, 210(1):42-48.
4. Noh KW, Pungpapong S, Wallace MB, et al. Do cytokine concentrations in pancreatic juice predict the presence of pancreatic diseases? Clin Gastroenterol Hepatol. 2006, 4(6):782-789.
5. Raimondo M, Imoto M, DiMagno EP. Rapid endoscopic secretin stimulation test and discrimination of chronic pancreatitis and pancreatic cancer from disease controls. Clin Gastroenterol Hepatol. 2003, 1(5):397-403.
6. Ohuchida K, Mizumoto K, Yu J, et al. S100A6 is increased in a stepwise manner during pancreatic carcinogenesis: clinical value of expression analysis in 98 pancreatic juice samples. Cancer Epidemiol Biomarkers Prev. 2007, 16(4):649-654.
7. Nakashima A, Murakami Y, Uemura K, et al. Usefulness of human telomerase reverse transcriptase in pancreatic juice as a biomarker of pancreatic malignancy. Pancreas. 2009, 38(5):527-533.
8. Tian M, Cui YZ, Song GH, et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer. 2008, 8:241.
9. Oliveira-Cunha M, Byers RJ, Siriwardena AK. Poly(A) RT-PCR measurement of diagnostic genes in pancreatic juice in pancreatic cancer. Br J Cancer. 2011, 104(3):514-519.
10. Kaur S, Baine MJ, Guha S, et al. Neutrophil gelatinase-associated lipocalin, macrophage inhibitory cytokine 1, and carbohydrate antigen 19-9 in pancreatic juice: pathobiologic implications in diagnosing benign and malignant disease of the pancreas. Pancreas. 2013, 42(3):494-501.
11. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature. 2008, 452(7187):571-579.
12. Macfarlane LA, Murphy PR. MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics. 2010, 11(7):537-561.
13. Wang J, Sen S. MicroRNA functional network in pancreatic cancer: from biology to biomarkers of disease. J Biosci. 2011, 36(3):481-491.
14. Xue Y, Abou Tayoun AN, et al. MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm. Cancer Genet. 2013, 206(6):217-221.
15. Thosani N, Dasari CS, Bhutani MS, et al. Molecular pathogenesis of intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 2010, 39(8):1129-1133.
16. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18(10):997-1006.
17. Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila). 2009, 2(9):807-813.
18. Ho AS, Huang X, Cao H, et al. Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. Transl Oncol. 2010, 3(2):109-113.
19. Liu J, Gao J, Du Y, et al. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer. 2012, 131(3):683-691.
20. Ryu JK, Matthaei H, Dal Molin M, et al. Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma. Pancreatology. 2011, 11(3):343-350.
21. Kong X, Du Y, Wang G, et al. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci. 2011, 56(2):602-609.
22. Li A, Yu J, Kim H, et al. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res. 2013, 19(13):3600-3610.
23. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. P Natl Acad Sci USA. 2008, 105(30):10513-10518.
24. Sadakari Y, Ohtsuka T, Ohuchida K, et al. MicroRNA expression analyses in preoperative pancreatic juice samples of pancreatic ductal adenocarcinoma. JOP. 2010, 11(6):587-592.
25. Sempere LF, Preis M, Yezefski T, et al. Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res. 2010, 16(16):4246-4255.
26. Greither T, Grochola LF, Udelnow A, et al. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer. 2010, 126(1):73-80.
27. du Rieu MC, Torrisani J, Selves J, et al. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem. 2010, 56(4):603-612.
28. Kent OA, Mullendore M, Wentzel EA, et al. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther. 2009, 8(21):2013-2024.
29. Jiang JM, Lee EJ, Gusev Y, et al. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res. 2005, 33(17):5394-5403.
30. Yu J, Ryan DG, Getsios S, et al. MicroRNA-184 antagonizes microRNA-205 to maintain SHIP2 levels in epithelia. P Natl Acad Sci USA. 2008, 105(49):19300-19305.
31. Wang X, Tang S, Le SY, et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PloS One. 2008, 3(7):e2557.
32. Fletcher AM, Heaford AC, Trask DK. Detection of Metastatic Head and Neck Squamous Cell Carcinoma Using the Relative Expression of Tissue-Specific Mir-205. Transl Oncol. 2008, 1(4):202-209.
33. Markou A, Tsaroucha EG, Kaklamanis L, et al. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem. 2008, 54(10):1696-1704.
34. Karaayvaz M, Zhang C, Liang SR, et al. Prognostic Significance of miR-205 in Endometrial Cancer. PloS One. 2012, 7(4).
35. Schaefer A, Jung M, Mollenkopf HJ, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010, 126(5):1166-1176.
36. Wszolek MF, Rieger-Christ KM, Kenney PA, et al. A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol. 2011, 29(6):794-801.
37. Giannakakis A, Sandaltzopoulos R, Greshock J, et al. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther. 2008, 7(2):255-264.
38. Porkka KP, Pfeiffer MJ, Waltering KK, et al. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007, 67(13):6130-6135.
39. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008, 141(5):672-675.
40. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65(16):7065-7070.
41. Camps C, Buffa FM, Colella S, et al. hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 2008, 14(5):1340-1348.
42. Gee HE, Camps C, Buffa FM, et al. hsa-mir-210 Is a Marker of Tumor Hypoxia and a Prognostic Factor in Head and Neck Cancer. Cancer. 2010, 116(9):2148-2158.
43. Chan YC, Banerjee J, Choi SY, et al. miR-210: The Master Hypoxamir. Microcirculation. 2012, 19(3):215-223.
44. Jung EJ, Santarpia L, Kim J, et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 2012, 118(10):2603-2614.
45. Shi S, Lu Y, Qin Y, et al. miR-1247 is Correlated with Prognosis of Pancreatic Cancer and Inhibits Cell Proliferation by Targeting Neuropilins. Curr Mol Med. 2014, 14:316-327.
46. von Frowein J, Pagel P, Kappler R, et al. MicroRNA-492 is Processed from the Keratin 19 Gene and Up-Regulated in Metastatic Hepatoblastoma. Hepatology. 2011, 53(3):833-842.